02 May 2024
// PRESS RELEASE
09 Apr 2024
// PRESS RELEASE
08 Apr 2024
// PRESS RELEASE
DATA COMPILATION
#PharmaFlow
Latest Content by PharmaCompass
About
CPhI Worldwide, MilanCPhI Worldwide, Milan
Industry Trade Show
Booth #24A21
08-10 October, 2024
Bio-Europe 2024Bio-Europe 2024
Industry Trade Show
Attending
04-06 November, 2024
CPhI India 2024CPhI India 2024
Industry Trade Show
Attending
26-28 November, 2024
CONTACT DETAILS
Events
Webinars & Exhibitions
CPhI Worldwide, Milan
Not Confirmed
Contact SupplierCPhI Worldwide, Milan
CPhI Worldwide, MilanCPhI Worldwide, Milan
Industry Trade Show
Booth #24A21
08-10 October, 2024
Bio-Europe 2024Bio-Europe 2024
Industry Trade Show
Attending
04-06 November, 2024
CPhI India 2024CPhI India 2024
Industry Trade Show
Attending
26-28 November, 2024
Digital content 
CORPORATE CONTENT #SupplierSpotlight
NEWS #PharmaBuzz
02 May 2024
// PRESS RELEASE
https://tiefenbacher-pharmaceuticals.com/2024/05/02/tiefenbacher-group-renovation-of-headquarters-in-hamburg/
09 Apr 2024
// PRESS RELEASE
https://tiefenbacher-pharmaceuticals.com/2024/04/09/tiefenbacher-first-to-market-launch-rivaroxaban/
08 Apr 2024
// PRESS RELEASE
https://tiefenbacher-pharmaceuticals.com/2024/04/08/tiefenbacher-group-welcomes-new-coo-sandip-tarate/
19 Mar 2024
// PRESS RELEASE
https://tiefenbacher-pharmaceuticals.com/2024/03/19/tiefenbacher-group-awarded-ecovadis-silver-medal/
29 Feb 2024
// PRESS RELEASE
https://tiefenbacher-pharmaceuticals.com/2024/02/29/tiefenbacher-group-on-awareness-for-rare-disease-day/
14 Feb 2024
// PRESS RELEASE
https://tiefenbacher-pharmaceuticals.com/2024/02/14/tiefenbacher-group-renovation-of-headquarters/
Drugs in Development
Details:
Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.
Lead Product(s): Rivaroxaban
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Xarelto-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 09, 2024
Lead Product(s) : Rivaroxaban
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Tiefenbacher Pharmaceuticals Successfully Prepares the Launch of The Anticoagulant Rivaroxaban.
Details : Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.
Product Name : Xarelto-Generic
Product Type : Small molecule
Upfront Cash : Not Applicable
April 09, 2024
Details:
Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.
Lead Product(s): Rivaroxaban
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Xarelto-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2023
Lead Product(s) : Rivaroxaban
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.
Product Name : Xarelto-Generic
Product Type : Small molecule
Upfront Cash : Not Applicable
November 16, 2023
Details:
Aubagio-Generic (teriflunomide) is a USFDA approved pyrimidine synthesis inhibitor which is indicated for the treatment of patients with relapsing forms of multiple sclerosis.
Lead Product(s): Teriflunomide
Therapeutic Area: Neurology Product Name: Aubagio-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2023
Lead Product(s) : Teriflunomide
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Aubagio-Generic (teriflunomide) is a USFDA approved pyrimidine synthesis inhibitor which is indicated for the treatment of patients with relapsing forms of multiple sclerosis.
Product Name : Aubagio-Generic
Product Type : Small molecule
Upfront Cash : Not Applicable
September 27, 2023
Details:
Bilastine Tiefenbacher (Bilastine) is a histamine H1 receptor inverse agonist, small molecule drug candidate which is indicated for the treatment of allergic rhino-conjunctivitis & urticaria.
Lead Product(s): Bilastine
Therapeutic Area: Immunology Product Name: Bilastine Tiefenbacher
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
Lead Product(s) : Bilastine
Therapeutic Area : Immunology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Bilastine Tiefenbacher (Bilastine) is a histamine H1 receptor inverse agonist, small molecule drug candidate which is indicated for the treatment of allergic rhino-conjunctivitis & urticaria.
Product Name : Bilastine Tiefenbacher
Product Type : Small molecule
Upfront Cash : Not Applicable
March 14, 2023
Details:
Otezla-Generic (apremilast) is an inhibitor of phosphodiesterase 4 (PDE4). It is indicated for the treatment of adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, and oral ulcers.
Lead Product(s): Apremilast
Therapeutic Area: Dermatology Product Name: Otezla-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2022
Lead Product(s) : Apremilast
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Otezla-Generic (apremilast) is an inhibitor of phosphodiesterase 4 (PDE4). It is indicated for the treatment of adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, and oral ulce...
Product Name : Otezla-Generic
Product Type : Small molecule
Upfront Cash : Not Applicable
December 01, 2022
Details:
Abiraterone and the combination product Abiraterone/Prednisolone are used to treat men with prostate cancer. The 500 mg (mono product) and 500 mg + 5 mg (combination product) tablets will be marketed in Europe by our partners.
Lead Product(s): Abiraterone Acetate,Prednisolone
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2022
Lead Product(s) : Abiraterone Acetate,Prednisolone
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Abiraterone and the combination product Abiraterone/Prednisolone are used to treat men with prostate cancer. The 500 mg (mono product) and 500 mg + 5 mg (combination product) tablets will be marketed in Europe ...
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
November 17, 2022
Details:
Apixaban Tiefenbacher (apixaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
Lead Product(s): Apixaban
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Apixaban Tiefenbacher
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2022
Lead Product(s) : Apixaban
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Apixaban Tiefenbacher (apixaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
Product Name : Apixaban Tiefenbacher
Product Type : Small molecule
Upfront Cash : Not Applicable
October 20, 2022
Details:
Vildagliptin/Metformin generic version launched in Africa market, the drug ais a diabetes medicine that are used to control the blood glucose (sugar) in adults with type 2 diabetes, by inhibiting DPP-4.
Lead Product(s): Vildagliptin,Metformin
Therapeutic Area: Endocrinology Product Name: Vildagliptin-Metformin-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2022
Lead Product(s) : Vildagliptin,Metformin
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Vildagliptin/Metformin generic version launched in Africa market, the drug ais a diabetes medicine that are used to control the blood glucose (sugar) in adults with type 2 diabetes, by inhibiting DPP-4.
Product Name : Vildagliptin-Metformin-Generic
Product Type : Small molecule
Upfront Cash : Not Applicable
September 08, 2022
Details:
Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.
Lead Product(s): Rivaroxaban
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Xarelto-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 15, 2022
Lead Product(s) : Rivaroxaban
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.
Product Name : Xarelto-Generic
Product Type : Small molecule
Upfront Cash : Not Applicable
July 15, 2022
Details:
Teriflunomide is a pyrimidine synthesis inhibitor with anti-inflammatory and immunomodulatory properties used to treat patients with the relapsing-remitting form of multiple sclerosis.
Lead Product(s): Teriflunomide
Therapeutic Area: Immunology Product Name: Teriflunomide-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Lead Product(s) : Teriflunomide
Therapeutic Area : Immunology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Teriflunomide is a pyrimidine synthesis inhibitor with anti-inflammatory and immunomodulatory properties used to treat patients with the relapsing-remitting form of multiple sclerosis.
Product Name : Teriflunomide-Generic
Product Type : Small molecule
Upfront Cash : Not Applicable
June 01, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Inspections and registrations
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
Market Place
Tiefenbacher
